FDA Approves First Orexin Agonist for Narcolepsy Type 1

The FDA approved oveporexton (Orzeyful), the first orexin receptor 2 agonist for treating narcolepsy type 1, showing significant symptom improvements including wakefulness and REM sleep normalisation based on phase 3 trials. The therapy introduces a first-in-class approach addressing orexin deficiency, with prescribing considerations for insomnia and potential DEA controlled-substance scheduling.

This Wire brief sits within Fusion42's coverage of Medtech, and 3 sources have reported it between 6 Aug 2026 and 21 Aug 2026.